Skip to main content
Literatur
1.
Zurück zum Zitat Yewdell JW (2021) Antigenic drift: understanding COVID-19. Immunity 54(12):2681–2687CrossRef Yewdell JW (2021) Antigenic drift: understanding COVID-19. Immunity 54(12):2681–2687CrossRef
2.
Zurück zum Zitat Andrews N et al (2022) Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med 386(4):340–350CrossRef Andrews N et al (2022) Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med 386(4):340–350CrossRef
3.
Zurück zum Zitat Barda N et al (2021) Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 385(12):1078–1090CrossRef Barda N et al (2021) Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 385(12):1078–1090CrossRef
4.
Zurück zum Zitat Munro APS et al (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398(10318):2258–2276CrossRef Munro APS et al (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398(10318):2258–2276CrossRef
6.
Zurück zum Zitat Nathan P et al (2021) Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med 385(13):1196–1206CrossRef Nathan P et al (2021) Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med 385(13):1196–1206CrossRef
7.
Zurück zum Zitat Lebwohl MG et al (2021) Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med 385(24):2219–2229CrossRef Lebwohl MG et al (2021) Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med 385(24):2219–2229CrossRef
Metadaten
Titel
Oh Omikron!
verfasst von
Wolfgang Weninger
Publikationsdatum
01.03.2022
Verlag
Springer Vienna
Erschienen in
hautnah / Ausgabe 1/2022
Print ISSN: 1866-2250
Elektronische ISSN: 2192-6484
DOI
https://doi.org/10.1007/s12326-022-00501-w

Weitere Artikel der Ausgabe 1/2022

hautnah 1/2022 Zur Ausgabe